Martin Wagner, Emina Halilbasic, Hanns‐Ulrich Marschall, Gernot Zollner, Peter Fickert, Cord Langner, Kurt Zatloukal, Helmut Denk, Michael Trauner – 28 June 2005 – Induction of hepatic phase I/II detoxification enzymes and alternative excretory pumps may limit hepatocellular accumulation of toxic biliary compounds in cholestasis. Because the nuclear xenobiotic receptors constitutive androstane receptor (CAR) and pregnane X receptor (PXR) regulate involved enzymes and transporters, we aimed to induce adaptive alternative pathways with different CAR and PXR agonists in vivo.

Heinz Zoller, Ian McFarlane, Igor Theurl, Sylvia Stadlmann, Elizabeta Nemeth, David Oxley, Tomas Ganz, David J. Halsall, Timothy M. Cox, Wolfgang Vogel – 28 June 2005 – Ferroportin disease (hemochromatosis type 4) is a recently recognized disorder of human iron metabolism, characterized by iron deposition in macrophages, including Kupffer cells. Mutations in the gene encoding ferroportin 1, a cellular iron exporter, are responsible for this iron storage disease, inherited as an autosomal dominant trait.

Hugo Girard, Jean Thibaudeau, Michael H. Court, Louis‐Charles Fortier, Lyne Villeneuve, Patrick Caron, Qin Hao, Lisa L. von Moltke, David J. Greenblatt, Chantal Guillemette – 28 June 2005 – PhIP (2‐amino‐1‐methyl‐6‐phenylimidazo[4,5‐f]pyridine), the most abundant heterocyclic amine in diet, is involved in the etiology of cancer. PhIP and its carcinogenic metabolite N‐hydroxy‐PhIP (N‐OH‐PhIP) are extensively conjugated by UDP‐glucuronosyltransferase (UGTs) with wide variability. This study aimed to determine the genetic influence of UGTs on the hepatic detoxification of this carcinogen.

Anna S. F. Lok, Marc G. Ghany, Zachary D. Goodman, Elizabeth C. Wright, Gregory T. Everson, Richard K. Sterling, James E. Everhart, Karen L. Lindsay, Herbert L. Bonkovsky, Adrian M. Di Bisceglie, William M. Lee, Timothy R. Morgan, Jules L. Dienstag, Chihiro Morishima – 28 June 2005 – Knowledge of the presence of cirrhosis is important for the management of patients with chronic hepatitis C (CHC). Most models for predicting cirrhosis were derived from small numbers of patients and included subjective variables or laboratory tests that are not readily available.

Nicola Villanova, Simona Moscatiello, Stefano Ramilli, Elisabetta Bugianesi, Donatella Magalotti, Ester Vanni, Marco Zoli, Giulio Marchesini – 24 June 2005 – Nonalcoholic fatty liver disease (NAFLD) is consistently associated with features of the metabolic syndrome, a condition carrying a high risk of cardiovascular events. We measured the vasodilatory response of the brachial artery in response to ischemia (a test of endothelial function) (FMV) as well as cardiovascular risk profile in 52 NAFLD cases and 28 age‐ and sex‐matched controls.

Luis Ruiz‐del‐Arbol, Alberto Monescillo, Carlos Arocena, Paz Valer, Pere Ginès, Víctor Moreira, José María Milicua, Wladimiro Jiménez, Vicente Arroyo – 23 June 2005 – The pathogenic mechanism of hepatorenal syndrome is not well established. We investigated the circulatory function in cirrhosis before and after the development of hepatorenal syndrome.

Savita Srivastava, Zobair M. Younossi – 23 June 2005

Benjamin L. Shneider, Ezequiel Neimark, Tamara Frankenberg, Lindsay Arnott, Frederick J. Suchy, Sukru Emre – 22 June 2005 – The Pediatric End‐Stage Liver Disease (PELD) scoring system is a new nationally utilized formula developed to provide a continuous numerical assessment of the risk of death in order to allocate livers to children for transplantation.

22 June 2005

Norah Terrault, Bruno Roche, Didier Samuel – 22 June 2005